Head-to-head · WeighScore
AquaVita NextGen vs FlyteHealth
The verdict
FlyteHealth takes it — 58.6/100 to 56.3/100.
FlyteHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FlyteHealth is an obesity-medicine telehealth platform distributed mainly through employers, payers, and health plans, with care led by board-certified obesity-medicine physicians plus nurse practitioners,…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AquaVita NextGen | FlyteHealth |
|---|---|---|
| WeighScore | 56.3/100 | 58.6/100 |
| Grade | C | C |
| Scorecard rank | #415 | #364 |
| Semaglutide | $375/mo (first-month rate, compounded) | Not disclosed |
| Tirzepatide | $320/mo (starting dose, 3-month plan, compounded) | Not disclosed |
| Coverage | 5 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #415 · C
Strengths
- Physical address in Lake Forest CA
- Named medical director (Dr. Steve Groke)
- Both semaglutide and tirzepatide including ODT tablets
- Compounding disclaimer present on site
Where it loses points
- Only 5 states (AZ, CA, FL, TX, NV)
- No LegitScript or PCAB accreditation
- Primarily a local medspa expanding into telehealth
- Only a first-month semaglutide price ($375, originally $499) is published; ongoing monthly price and all tirzepatide pricing remain unpublished
Graded #364 · C
Strengths
- Care led by board-certified obesity-medicine physicians
- Multidisciplinary team with NPs, dietitians, and care coordinators
- Published outcomes of about 13 to 16 percent weight loss over 12 months
- High GLP-1 medication adherence (around 86 percent in reported data)
- Comprehensive cardiometabolic care beyond GLP-1 alone
Where it loses points
- Distributed primarily via employers, payers, and health plans, not direct cash-pay
- Access is largely gated behind employer or plan sponsorship
- GLP-1 is prescribed only when appropriate, not guaranteed
- Self-pay pricing is not publicly listed (contact required)
- Less suited to consumers wanting fast direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.